GlassScriptPhysician profile
Charles Grodzin
NPI 1215904859
$3,446.60
in general payments reported to CMS, 2019-2025
11 companies · $36.77 in 2025
The $36.77 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $15.45 · 2022: $130 · 2023: $2,039 · 2024: $1,064 · 2025: $36.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,700 · Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,700.00 |
| Food and Beverage | $440.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aidoc Medical LTD | $2,700.00 | 2023-2024 | Briefcase |
| Penumbra, INC. | $195.27 | 2023-2024 | Indigo System, Ruby Coil |
| Inari Medical, INC. | $133.76 | 2019 | |
| Viz.Ai, INC. | $130.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.00 | 2023 | Xarelto |
| Boston Scientific Corporation | $88.04 | 2024 | Ekosonic |
| Verona Pharma, INC. | $23.24 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Ethicon US, LLC | $13.53 | 2025 | N/A |
| Genentech USA, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Grodzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.